Product-market fit in stem cell TechBio: building for workflows, not for papers

Reading time: 7 minutes

The preceding articles in this Pillar 2 series examined failure modes that are specific to building technology for biology: reproducibility, scale-up, characterisation gaps, cryopreservation, toolchain fragmentation, and the regulatory cliff. Each is a technical or operational obstacle that can stall or kill a company with sound science. But the most common reason startups fail across all sectors is not technical. It is a failure to build something the market actually needs.

Across the broader startup landscape, absence of market demand consistently ranks as the leading cause of failure, ahead of running out of cash and team breakdown (Source Document). In ancillary TechBio for stem cell science, this problem takes a distinctive and often underappreciated form. The tools that fail are frequently impressive. They work. They are based on real science. They address a real limitation. But they are built for the wrong user, the wrong workflow, or the wrong stage of the market's development.

Where academic strength becomes commercial weakness

Many ancillary technologies for stem cell science originate in academic laboratories. This is both a strength and a structural risk. Academic incentives reward novelty, technical sophistication, and publication. Commercial incentives reward consistency, usability, cost-effectiveness, and integration into existing workflows. A product optimised for one set of incentives may be poorly suited to the other.

The pattern is recognisable. A research group develops a tool that solves a problem they encounter in their own work. It performs well in their hands, produces publishable data, and attracts interest at conferences. A company is formed. The product is launched. And then it stalls, because the problem it solves in one laboratory is not the problem that limits throughput, quality, or cost in the facilities where purchasing decisions are made.

This is not a failure of science. It is a failure of scope. The technology may be genuinely useful, but for a different user, a different application, or at a different price point than the one the company is pursuing. A platform designed for discovery research may have real value there but none in manufacturing. A tool optimised for a specific cell type in a specific protocol may not generalise to the range of conditions a commercial customer requires. The question is not whether the technology works. It is whether the specific product built around that technology addresses a need that someone will pay to solve, repeatedly, at a price that sustains the business.

Who is your buyer and what are they actually doing

The stem cell field spans a wide range of users with different needs. A tool that serves an academic research laboratory, a cell therapy manufacturing facility, a contract development and manufacturing organisation (CDMO), and a pharmaceutical screening operation does not need to do the same thing for each. The workflows differ, the quality standards differ, the purchasing processes differ, and the willingness to adopt new technology differs.

Academic researchers typically adopt new tools based on performance and novelty. They have flexibility to modify protocols, tolerate complexity, and invest time in optimisation. They are also price-sensitive in absolute terms but less concerned with cost-per-unit at scale. Their procurement decisions are often made by individual principal investigators.

Manufacturing operations adopt tools based on consistency, regulatory compatibility, integration with existing systems, and total cost of ownership. Their tolerance for complexity is low. Their procurement decisions are made by cross-functional teams including quality, regulatory, operations, and finance. A product that cannot demonstrate validated performance, supply chain reliability, and regulatory fitness will not pass evaluation, regardless of its scientific merit. The regulatory cliff article describes what this evaluation looks like in practice.

CDMOs serve multiple clients and need tools that are flexible across cell types and applications but also standardisable within their quality systems. They are important gatekeepers because a product that is adopted by a CDMO reaches many downstream users.

Understanding which of these buyers you are serving, and designing your product, your validation programme, and your commercial messaging accordingly, is not a marketing exercise. It is a product development decision that shapes everything from material choices to user interface design.

Testing demand before you build

The most expensive way to discover that no one needs your product is to finish building it. The stem cell field is littered with technologies that were developed to completion, launched at conferences, and met with polite interest followed by no purchases. The failure was not that the product did not work. It was that the company did not test demand early enough.

Demand validation in ancillary TechBio is harder than in software. You cannot ship a minimum viable product in weeks. Biology takes time, and validating a cell culture tool against real workflows takes months. But the principle of early testing still applies, and several approaches are available.

Workflow shadowing. Spending time in the laboratories and manufacturing facilities of potential customers, observing their actual workflows rather than their published protocols, reveals where the friction is. The bottleneck your technology addresses may not be the bottleneck the user cares most about. The step you automate may not be the step that limits throughput. The measurement you improve may not be the measurement the quality team uses for release decisions.

Problem interviews before solution development. Talking to potential buyers about the problems they face, before describing your solution, tests whether the need is real and whether the user would pay to solve it. This is standard practice in product development generally but is underused in TechBio, where founders are often deep technical experts who are confident they understand the problem because they have experienced it themselves. Your experience of the problem in your laboratory may not match the experience of the problem in a manufacturing facility.

Pilot evaluations with defined success criteria. When you do have a prototype, placing it with a small number of users under conditions that approximate real use, with agreed metrics for success, generates evidence that either supports or contradicts your product-market assumptions. The reproducibility article described how pharmaceutical partners evaluate ancillary technologies. Running a version of that evaluation process yourself, before the partner does, lets you find and address problems on your own terms.

The positioning gap

Even when a product addresses a real need, companies frequently struggle to articulate why it matters in terms the buyer understands. The language of the academic paper, mechanism of action, statistical significance, comparison with prior art, is not the language of the procurement decision. Buyers want to know: what does this do for my workflow, how much does it cost per unit, how does it integrate with my existing systems, what evidence supports its performance under my conditions, and what happens if it fails.

Pillar 3 in this blog series addresses positioning in detail. For the purposes of this article, the key point is that product-market fit is not just about building the right product. It is about framing it correctly for the buyer who needs it.

Where this series lands

This article completes the Pillar 2 series on why ancillary technologies for stem cell science fail. The failure modes covered across these articles are not independent. They compound. A product that is difficult to reproduce at scale, that cannot be adequately characterised with current assays, that loses quality through the cold chain, that does not integrate with the rest of the workflow, that cannot navigate the regulatory transition, and that addresses a need the market does not prioritise, is a product with multiple simultaneous vulnerabilities.

The companies that succeed will be those that recognise these interdependencies early and design for them. Not sequentially, addressing reproducibility first, then scale, then regulation, then market fit, but in parallel. The biology, the engineering, the regulation, and the commercial reality all have to work together. That is a higher bar than most startups anticipate, but it is the bar that this field sets.

The Pillar 1 series on developmental and stem cell biology provides the scientific foundation. This Pillar 2 series has mapped the failure landscape. Pillar 3 turns to the constructive question: how to position and develop a TechBio product that avoids these failures and finds its place in the market.

About StemCells.Help

StemCells.Help is an advisory consultancy that aids innovation and real-world impact of life science applications built on developmental and stem cell biology. Founded by Dr Paul De Sousa, it draws on over four decades of experience spanning early embryo development, animal cloning, pluripotent stem cell manufacturing, and technology commercialisation. If you build tools for these domains or work in an emerging application where the biology is the enabling technology, StemCells.Help can provide experienced scientific counsel to ground your decisions. To discuss your needs, talk to Paul.

ORCID: 0000-0003-0745-2504

Web: stemcells.help